J. Charles Homcy's most recent trade in Maze Therapeutics Inc. was a trade of 1,489 Common Stock done . Disclosure was reported to the exchange on Nov. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Maze Therapeutics Inc | Charles J. Homcy | Director | Other type of transaction at price $ 0.00 per share. | 19 Nov 2025 | 1,489 | 31,113 | - | 0 | Common Stock | |
| Maze Therapeutics Inc | Charles J. Homcy | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Oct 2025 | 28,423 | 29,624 | - | 0 | Common Stock | |
| Maze Therapeutics Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2025 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Sale of securities on an exchange or to another person at price $ 45.87 per share. | 08 Aug 2025 | 191,662 | 1,025,012 (0%) | 0% | 45.9 | 8,791,593 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Sale of securities on an exchange or to another person at price $ 46.64 per share. | 08 Aug 2025 | 58,338 | 966,674 (0%) | 0% | 46.6 | 2,720,849 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Sale of securities on an exchange or to another person at price $ 48.00 per share. | 08 Aug 2025 | 50,000 | 916,674 (0%) | 0% | 48 | 2,400,000 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Jun 2025 | 20,000 | 1,216,674 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 8,425 | 8,425 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 6,589 | 1,236,674 (0%) | 0% | 0 | Common Stock | |
| Maze Therapeutics Inc | Charles J. Homcy | Director | 03 Feb 2025 | 169,405 | 0 | - | - | Series C Preferred Stock | ||
| Maze Therapeutics Inc | Charles J. Homcy | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 80,385 | 0 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 80,385 | 80,385 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Charles J. Homcy | Director | 03 Feb 2025 | 72,727 | 0 | - | - | Series B Preferred Stock | ||
| Maze Therapeutics Inc | Charles J. Homcy | Director | 03 Feb 2025 | 71,564 | 7,422 | - | - | Series D-1 Preferred Stock | ||
| Maze Therapeutics Inc | Charles J. Homcy | Director | 03 Feb 2025 | 71,564 | 0 | - | - | Series D-1 Preferred Stock | ||
| Maze Therapeutics Inc | Charles J. Homcy | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 46,675 | 0 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 46,675 | 46,675 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 45,638 | 45,638 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Charles J. Homcy | Director | 03 Feb 2025 | 20,717 | 58,047 | - | - | Common Stock | ||
| Maze Therapeutics Inc | Charles J. Homcy | Director | 03 Feb 2025 | 8,807 | 37,330 | - | - | Common Stock | ||
| Maze Therapeutics Inc | Charles J. Homcy | Director | 03 Feb 2025 | 7,422 | 7,422 | - | - | Common Stock | ||
| Maze Therapeutics Inc | Charles J. Homcy | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 5,704 | 0 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 5,704 | 5,704 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 26,014 | 26,014 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Homcy J. Charles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 3,760 | 1,231,594 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 3,760 | 0 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | J. Charles Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.21 per share. | 16 Feb 2024 | 1,509 | 1,230,085 (0%) | 0% | 37.2 | 56,150 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 3,760 | 1,225,838 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 3,760 | 7,520 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.80 per share. | 16 Aug 2023 | 1,301 | 1,224,537 (0%) | 0% | 29.8 | 38,770 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 51,501 | 51,501 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 3,759 | 11,280 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 3,759 | 1,222,127 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.09 per share. | 16 May 2023 | 1,300 | 1,220,827 (0%) | 0% | 14.1 | 18,317 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 3,760 | 15,039 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 3,760 | 1,219,902 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.64 per share. | 16 Feb 2023 | 1,534 | 1,218,368 (0%) | 0% | 12.6 | 19,390 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 3,760 | 22,559 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 3,760 | 1,210,742 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.08 per share. | 16 Aug 2022 | 1,287 | 1,209,455 (0%) | 0% | 11.1 | 14,260 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 104,921 | 104,921 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 3,759 | 1,208,523 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 3,759 | 26,319 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.74 per share. | 16 May 2022 | 1,541 | 1,206,982 (0%) | 0% | 6.7 | 10,386 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 30,078 | 30,078 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2021 | 55,011 | 55,011 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 38,895 | 38,895 | - | - | Stock Option (right to buy) |